Welcome to our dedicated page for Aquestive Therapeutics news (Ticker: AQST), a resource for investors and traders seeking the latest updates and insights on Aquestive Therapeutics stock.
Aquestive Therapeutics, Inc. develops and manufactures specialty pharmaceutical products using proprietary oral-film and drug-delivery technologies. News about AQST centers on the company’s proprietary pipeline, including Anaphylm™ (dibutepinephrine) sublingual film for Type I allergic reactions, including anaphylaxis, and AQST-108, an epinephrine prodrug topical gel being explored for dermatological conditions such as alopecia areata.
Recurring updates also cover FDA interactions and NDA communications for Anaphylm, pharmacokinetic and human-factor study topics, quarterly financial results, licensee and CDMO manufacturing activity, investor presentations, equity inducement grants, and legal, compliance, and board-governance changes.
Aquestive Therapeutics (NASDAQ:AQST) reported Q1 2026 revenue of $14.4 million, up 66% year over year, and a net loss of $8.1 million versus $22.9 million in Q1 2025. Non-GAAP adjusted EBITDA loss was $1.7 million.
The company reaffirmed plans to resubmit the Anaphylm NDA in Q3 2026, advanced ex-US regulatory work, completed a phase 1 study of AQST-108, and entered a new $150 million debt facility with Oaktree, expecting $150 million in launch liquidity if Anaphylm is approved in 2027.
Aquestive Therapeutics (NASDAQ:AQST) refinanced its existing debt with a new $150 million five-year facility from Oaktree Capital Management. The deal funds repayment of a $45 million loan and offers interest-only payments with principal due at maturity.
The facility includes an initial $55 million funded at closing, $20 million upon FDA approval of Anaphylm and other conditions, a $25 million sales milestone tranche, and up to $50 million subject to mutual consent, enhancing flexibility for a potential Anaphylm launch and meeting conditions under a strategic funding agreement with RTW Investments.
Aquestive Therapeutics (NASDAQ: AQST) will report first quarter 2026 financial results for the period ended March 31, 2026 after market close on Wednesday, May 13, 2026, and will host a conference call at 8:00 a.m. ET on May 14, 2026.
A live webcast will be available in the Investors section of Aquestive's website, and a replay will be archived for 30 days.
Aquestive Therapeutics (NASDAQ: AQST) completed a Type A meeting with the FDA on March 30, 2026, for Anaphylm (dibutepinephrine) sublingual film. The company received clarifying FDA feedback on PK and human factors (HF) study designs, will address comments, and reaffirms an NDA resubmission planned for Q3 2026. Final FDA meeting minutes are expected by early May 2026. FDA acknowledged container closure revisions and aligned on labeling language to address potential chewing of the film. Aquestive is also advancing regulatory filings in Canada and the EU.
Aquestive Therapeutics (NASDAQ: AQST) appointed Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026. Lori J. Braender will step down from those executive roles and remain as Corporate Secretary.
The company granted an inducement package of 100,000 RSUs and 75,000 options; awards vest 25% after years one and two and 50% in year three, with options exercisable for ten years and priced at the closing share price on May 8, 2026.
Aquestive Therapeutics (NASDAQ: AQST) granted inducement equity awards to Matthew Greenhawt, its newly hired Chief Medical Officer, under the 2022 Equity Inducement Plan. The awards total 75,000 RSUs and 50,000 non‑qualified stock options to be granted on March 9, 2026.
The awards vest 25% after each of the first and second anniversaries and 50% on the third anniversary, the options have a ten‑year term and an exercise price equal to the March 9, 2026 closing price. Awards rely on Nasdaq Listing Rule 5635(c)(4) and were approved by the independent Compensation Committee.
Aquestive Therapeutics (NASDAQ: AQST) reported Q4 and full‑year 2025 results and a business update on March 4, 2026. Q4 revenue rose 10% to $13.0M driven by manufacture and supply; the company manufactured ~47M doses in Q4. Management received an FDA Complete Response Letter for Anaphylm and plans a Type A meeting and NDA resubmission in Q3 2026. Aquestive guides to ~$70M cash at year‑end FY2026 and closed amendments with RTW including a $5.0M minimum share purchase commitment.
Aquestive Therapeutics (NASDAQ:AQST) said its management team will attend four investor conferences in March, including TD Cowen, Leerink Partners, Citizens Life Sciences, and Barclays.
Presentations, a Leerink fireside chat, and 1x1 meetings are scheduled; webcasts and 30-day replays will be posted on the company's Investors "Events and Presentation" page.
Aquestive Therapeutics (NASDAQ: AQST) will report fourth-quarter 2025 financial results after market close on Wednesday, March 4, 2026, and will provide recent business updates.
Management will host a conference call for investors on March 5, 2026 at 8:00 a.m. ET with a live webcast and a 30-day replay available on the company investor website.
Aquestive Therapeutics (NASDAQ: AQST) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, a virtual event on February 25-26, 2026. Management will present on February 26 at 12:00 PM ET and will hold investor one-on-ones the same day.
A webcast will be available on the company’s Investors "Events and Presentations" page, with a replay accessible for 30 days following the presentation.